Skip to Content

View Additional Section Content

Heart and Vascular Center

Cardiovascular Clinical Research

The University of Missouri Health System has conducted clinical trials for more than 40 years. Many of these trials have resulted in approval of new drugs from the Food and Drug Administration. The broad experience of our research team combined with our wide range of clinical opportunities makes the health system an attractive site for conducting clinical research.

Volunteers help speed future improvements in medical care to those in need. The University of Missouri Health System has a broad base of clinical trial opportunities available to volunteers such as you. Talk with your physician about participating in these trials. 

To refer a patient to any cardiovascular medicine trial page the on-call pager number 573-499-8084.

Clinical Trials Currently Enrolling

Iron Out

  • Danila/Chockalingam

Oral ion vs. Placebo-Oral iron repletion effects on oxygen uptake in heart failure


  • Weachter/Gautam/Flaker

Apixaban vx. Warfarin – New-onset A-Fib with the intent to cardiovert. Must enroll prior to dosing with oral anticoagulant.


  • Webel/Aggarwal/A. Kumar/A. Chan

Open label study to assess the long-term safety and efficacy of Evolocumab treatment for addtioanl LDL-cholesterol reduction.

Registry Trials Currently Enrolling


  • Weachter/Flaker/Sullivan

Post-market surveillance to document product performance assessment of Medtronic device leads

Ongoing Clinical Trials - Not Enrolling

Reveal Timi--55

  • Aggarwal/Webel

Does inhibition of cholesteryl ester transfer protein (Anacetrapib vs. Placebo) prevent major vascular events in patients with vascular disease?


  • Flaker/Weachter

Late Sodium Current Blockade in High-Risk ICD patients using Ranolazine vs. Placebo


  • Webel/Aggarwal/Kumar

Canakinumab vs. Placebo in the prevention of recurrent cardiovascular events in Post-MI patients with elevated hsCRP


  • Webe/Aggarwal/A.Kumar/Chan

The Effects of AMG 145 vs. Placebo on Atherosclerotic disease burden as measured by IVUS in subjects undergoing coronary catheterization


  • Webel/Aggarwal/A.Kumar/Chan

Assessing the impact of additional LDL-C reduction on MACE when AMG 145 vs. Placebo is used in combination with statin therapy in patients with clinically evident CV disease

Schedule an Appointment

To schedule an appointment, contact:

Cardiology and Cardiovascular Medicine:

Cardiothoracic Surgery: 

Vascular Surgery: